chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Vaccine  stored on the fridge for more than 30 days prior to first use.; Dose administered to 10 patients after more than 30days of storage in the fridge; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Dose administered to 10 patients after more than 30days of storage in the fridge) and PRODUCT STORAGE ERROR (Vaccine  stored on the fridge for more than 30 days prior to first use.) in a 30-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 033H21A) for COVID-19 vaccination.     No Medical History information was reported.    On 04-Feb-2022, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 04-Feb-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Dose administered to 10 patients after more than 30days of storage in the fridge). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Vaccine  stored on the fridge for more than 30 days prior to first use.). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Dose administered to 10 patients after more than 30days of storage in the fridge) and PRODUCT STORAGE ERROR (Vaccine  stored on the fridge for more than 30 days prior to first use.) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant products were reported.  HCP stated there were 4 vials from Moderna COVID-19 Vaccine that were stored on the fridge for more than 30 days prior to first use. Vials were stored in the fridge since 22-Dec-2021.  No treatment information was reported by the reporter.
DIZZINESS; NO PATIENCE; DEPRESSED; NO APPETITE; ARM PAIN; FEVER; MUSCLE ACHE; NAUSEA; HEADACHE; This spontaneous report received from a patient concerned a female of unspecified age. The patient's weight, height, and medical history were not reported.The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1802072, expiry: 25-MAY-2021) dose was not reported, once a total administered on 08-MAR-2021 for prophylactic vaccination. No concomitant medications were reported. On MAR-2021, the subject experienced dizziness. On MAR-2021, the subject experienced no patience. On MAR-2021, the subject experienced depressed. On MAR-2021, the subject experienced no appetite. On MAR-2021, the subject experienced arm pain. On MAR-2021, the subject experienced fever. On MAR-2021, the subject experienced muscle ache. On MAR-2021, the subject experienced nausea. On MAR-2021, the subject experienced headache. Laboratory data included: Body temperature (NR: not provided) 102 (units unspecified). Laboratory data (dates unspecified) included: COVID-19 virus test (NR: not provided) Negative. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from fever, muscle ache, nausea, headache, arm pain, depressed, no appetite, dizziness, and no patience. This report was non-serious.
Headache, Myalgia, Diarrhea, Cills Narrative:
Our daughter took Pfizer booster shot and ended up with hives, swollen lips, and face. The hives are now everyday routine. We are very worried about or child. Allergists have tried everything and it is not helping. It has been damaging our child physically and mentally. Please help.
Pt received flu vaccine at 11am in the L Deltoid at work. Around 4:30pm patient felt left facial numbness and hives and redness on her cheeks. Upon getting home that evening (between 5 and 5:30pm), patient took 1 Benadryl and reaction subsided.
Patient developed fever and malaise for four days followed by development of persistent fatigue and positional vertigo.
GOOSEBUMPS THROUGHOUT THE NIGHT AND THE FOLLOWING DAY; CHILLS THROUGHOUT THE NIGHT AND THE FOLLOWING DAY; STRONG HEADACHE THROUGHOUT THE NIGHT AND THE FOLLOWING DAY; This spontaneous report received from a consumer concerned a male of unspecified age. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported.The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: UNKNOWN) dose was not reported, administered on 01-JUN-2021 for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported. On 01-JUN-2021, the subject experienced goosebumps throughout the night and the following day. On 01-JUN-2021, the subject experienced chills throughout the night and the following day. On 01-JUN-2021, the subject experienced strong headache throughout the night and the following day. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the strong headache throughout the night and the following day, chills throughout the night and the following day and goosebumps throughout the night and the following day was not reported. This report was non-serious. This case, from the same reporter is linked to 20210611877.
Pt reports dizziness, headache & nausea. Pt seen by ER physician. Diagnosed with possible migraine or inner ear problem.
This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. A 24 year-old patient received bnt162b2 (BNT162B2), intramuscular, administered in arm left, administration date 13May2021 (Lot number: EW0161, Expiration Date: 20Jul2021) as dose 2, single for Covid-19 immunisation. Relevant medical history included: "COVID-19", start date: 06Jan2021 (unspecified if ongoing), notes: Hospitalized for 5 days. The patient's concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose 1, Site of injection: left arm, Site and route of injection: left arm, Batch/Lot no: ER8733 Exp.: 20Jul2021), administration date: 22Apr2021, for Covid-19 immunisation, reaction(s): "Lethargic", "fever". The following information was reported: INFLUENZA (non-serious) with onset 14May2021, outcome "recovered" (2021), described as "Flu Symptoms". Relevant laboratory tests and procedures are available in the appropriate section. Additional information: Vaccination facility type was other. No prior vaccination. The patient tested positive for Covid-19 on 06Jan2021 and hospitalized for 5 days and again Covid antibody test positive on 09Apr2021 which was prior to commencement of vaccine. No follow-up attempts are possible. No further information is expected.
Information has been received from a registered nurse concerning an adult patient, on dialysis, who was vaccinated with the primary series of RECOMBIVAX HB in the past (dates unspecified), and now is showing "negative titers". Unspecified medical attention was sought. There was no product quality complaint. At the time of reporting the patient was not yet recovered. Attempts are being made to obtain additional identifying information to distinguish the individual patient mentioned in this report. Additional information will be provided if available. This is one of several reports received from the same source. Additional information has been requested.
Redness, swelling, warmth to (R) upper arm at injection site. No treatment.
Redness and swelling at site right deltoid. Very tender to touch. itchy Seen in Dr. office 9-11-08
Fever 101.8 Day of vaccine x 24 hr Vomiting x 1 Redness/tender @ sight of  PCV/Hib
Pt noted non-pruritic rash on chest, 1 day, post vax, 1st Hep-B . Rash appeared intermittent, post vax, 2nd Hep-B, 1 month later, rash became more diffuse and now is pruritic.
Information has been received from a medical assistant referring to a 4 years old female patient. The patient's medical history, concurrent conditions and concomitant medications were not reported. On 12-JUN-2015, the patient was vaccinated with an improperly stored dose of M-M-R II (lot # K021151 with expiration date 02-NOV-2016; dose and route of administration were not reported). No adverse effects were reported. This is one of several cases received from the same source,. Additional information has been requested.
Received Tdap and Hep B adult on April 27, 2007.  Phoned Health Department four days later on May 1st to report "rash and bumps moving down the right arm" starting on April 28th.  Area reddened, warm to touch with "bump" at injection site.  Denies hives, fever, or signs of cellulitis such as streaking and swelling of limb. Now has similar rash on left arm.  Recommened ibuprofen for pain and swelling, as well as appropriate use of heat and cold.  Suggested evaluation by MD as is concerned about receiving the rest of her Hep B series; does not want to do so, is very busy with classes. Called her the next day to  check on progress.  Did not use any comfort measures as suggested, and while not worse, had not improved.  On May 10th at 8PM, she returned phone call after hours  in response to another from me phone message asking about her progress and requesting more information for a VAERS report   A total of 5 calls were made, including two evening calls when she suggested per voice mail that this is the best time to reach her. The last call was yesterday, June 4th, 20007.  I left a message at that time stating that I would file the report with the information on hand unless she wished to add or make any changes to what we discussed.  I did not receive a response.
Patient admitted 5/17. The patient complains of left and right lower abdominal pain associated with nausea and vomiting.  She was evaluated in the ED and was found to have COVID-19 infection 5/17.  Patient also complained of having chest pain.  Patient describes that her chest pain started before the nausea and vomiting and feels like a sting and then the nausea and vomiting started.  She describes having a syncopal event PTA. Patient does have a history of chronic abdominal pain.  The patient underwent an ultrasound of the abdomen, which revealed findings consistent with cholelithiasis, no evidence of cholecystitis.  No fevers, no chills. Dishcharged home 5/22.
Daughter call in for VAERS report to file for father whom committed suicide 1/16/2021 in the AM after reportable ae of COVID 19 vaccine administered 1/14/2021.  Patient sought care twice at  ER; first visit by ambulance around 5PM and Friday 1/15/2021 Medical Center: Emergency Room.  1st Discharge summary diagnosis: adverse reaction to COVID shot; 2nd Discharge summary diagnosis: adverse reaction to COVID shot, fever, Panic Disorder-- ER. Medical Center Discharge summary diagnosis: Adverse reaction to the vaccine, acute anxiety. Reportable patient symptoms at, 1st visit : fever, shaking stomach cramps, breathing issues.  Medical Center  -- No fever, confusion and dementia type, patient would not stay in patient bed; patient would get up and sit down again repeatedly, agitated and anxious. Attempted to urinated hospital bed.  Patient committed suicide in home.
In March, I found out I was pregnant. We found d out the baby had chromosomal abnormalities. Not long after finding out, I had surgery to terminate the pregnancy. In October 2022, I tested positive for COVID-19. I had a sore throat, congestion, cough, and fever. I took TYLENOL for the fever and after two weeks of coughing, I contacted my doctor and was prescribed albuterol.
A report has been received from a Health Professional concerning a child, subject of unknown gender, who had been receiving FLUMIST QUADRIVALENT (intranasal). FLUMIST QUADRIVALENT (intranasal) started on an unknown date. It was reported that the patient child was taking aspirin for a year received FLUMIST QUADRIVALENT. The outcome of the event of child taking aspirin for a year received FLUMIST QUADRIVALENT is unknown. The report was considered to be non-serious.
Left deltoid with progressive cellulitis.  Oral antibiotics started. Versus significant inflammatory response-nurse recall of struggle at time of immunization
tested positive for COVID-19; This spontaneous case was reported by a nurse and describes the occurrence of COVID-19 (tested positive for COVID-19) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form and second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced COVID-19 (tested positive for COVID-19). At the time of the report, COVID-19 (tested positive for COVID-19) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, SARS-CoV-2 test: positive (Positive) Positive.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No relevant concomitant medications were reported. Treatment information was unknown.  Company comment: This spontaneous case concerns a patient of unknown age and gender, with no reports on medical history, who experienced the non-serious unexpected AESI of COVID-19. The event occurred on an unknown date after receiving a third dose of mRNA-1273. Vaccination dates were not provided; hence schedule cannot be assessed. No further clinical information was available for medical reviewing. The benefit-risk relationship of mRNA-1273 is not affected by this report.    Reporter did not allow further contact; Sender's Comments: This spontaneous case concerns a patient of unknown age and gender, with no reports on medical history, who experienced the non-serious unexpected AESI of COVID-19. The event occurred on an unknown date after receiving a third dose of mRNA-1273. Vaccination dates were not provided; hence schedule cannot be assessed. No further clinical information was available for medical reviewing. The benefit-risk relationship of mRNA-1273 is not affected by this report.
Sore arm within an hour; Chills; body aches; fatigue overnight and throughout the next day; slight headache; This is a spontaneous report from a contactable nurse (patient).  A 24-year-old female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE) lot number: Eh9899, via intramuscular route in the right arm, first dose on 21Dec2020 11:00 at a single dose for immunization. Medical history was none. The patient's concomitant medications were not reported. The patient is not pregnant. She has no known allergies. The patient did not have Covid prior vaccination and was not tested post vaccination. She did not receive other vaccines with 4 weeks prior to covid vaccine. The patient experienced sore arm within an hour on 21Dec2020 with outcome of recovering. She also had chills, body aches, fatigue overnight and throughout the next day with outcome of recovering. Almond with slight headache which was recovering. No treatment received for the events. The seriousness of the events was reported as non-serious.
DIZZINESS; SLEEPINESS; HEADACHE; NAUSEA; This spontaneous report received from a patient concerned a 51 year old female. The patient's weight, height, and medical history were not reported.The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 201A21A, and  expiry: UNKNOWN) dose was not reported, administered on 06-APR-2021 for prophylactic vaccination. No concomitant medications were reported. On 06-APR-2021, the subject experienced dizziness. On 06-APR-2021, the subject experienced sleepiness. On 06-APR-2021, the subject experienced headache. On 06-APR-2021, the subject experienced nausea. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from headache, dizziness, nausea, and sleepiness. This report was non-serious.
Central Retinal Vein Occlusion 1 day after receiving second dose of Pfizer vaccination + Thrombocytopenia
Information has been received from a physician concerning a multiple patients (no demographics provided) who on unspecified dates were vaccinated with GARDASIL vaccine (yeast) (lot #s unspecified) and had stinging at the injection site. At the time of this report the outcome was unknown. Attempts are being made to obtain additional identifying information to distinguish the individual patients mentioned in this report. Additional information will be provided when available. Additional information has been requested.
Patient noticed swelling of her left supraclavical lymphnode 2 days after recieving influenza (FLULAVAL QUAD) vaccine.  Patient recieved ultrasound.  The ultrasound showed a significant increase in size at 1.5cm.  The physician then ordered a surgeon follow up where the surgeon reviewed the ultrasound and also palpated the injury site of the patient. The physician noted the node was decreasing in size, was mobile and shrinking and decided to monitor for now. The physician called it a reactive node and scheduled a follow up appointment in 3 months with the patient.  When patient recieved COVID-19  Booster on 09/30/2021, patient also experienced the same symptoms of her left node being reactive and increased in size.
Both dose I presented with an allergic square breakout big bumps and itching a lot. I had ALLERGRA to relieve the allergy.
I am an extremely regular person when it comes to my period. It is 28 days, down to the hour. The period after my first dose was three days late. It was heavier than normal, and I had some severe body aches. When I got my second dose, I experienced fatigue and body aches for a few days after. For about 10 days before my period I experienced incredibly achey breasts (this usually happens just  1-2 days before, and medium ache). Just got my period this morning, 2 days early. My whole body is achy, and the flow is really heavy.
Patient had history of hives in reaction to 1st dose of Pfizer COVID-19 vaccine. Patient evaluated by Allergist/Immunologist and was cleared to receive the 2nd dose of vaccine with precaution. Patient was given 10 mg of Cetirizine prior to vaccination. Approximately 10 minutes after vaccine administration, patient complained of itching in scalp area. Patient denied difficulty breathing and was able to speak well in complete sentences.  BP 122/69, O2 sat 98% HR 69. Patient monitored.
Of my feet itched like something I have never experienced; rash on my thighs; fatigue; headache; blurry vision; still to this day swollen lymph nodes.; This is a spontaneous report from a contactable consumer.A 42-years-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), dose 2 via an unspecified route of administration, administered in Arm Left on 09Apr2021 16:45 (Batch/Lot Number: EW0158) as DOSE 2, SINGLE for covid-19 immunisation.  Medical history included allergy with Sulfa drugs. Concomitant medication(s) included lorazepam (ATIVAN) taken for an unspecified indication, start and stop date were not reported; cetirizine hydrochloride (ZYRTEC ALLERGY) taken for an unspecified indication, start and stop date were not reported. Patient previously received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) (lot number:ER8736) on 01May2021 administrated in left arm for covid-19 immunization.After second dose, within 5 days , the bottom Of my feet itched like something I have never experienced, rash on my thighs, fatigue, headache, blurry vision, still to this day swollen lymph nodes. Outcome of swollen lymph nodes was not recovered, of others was recovering. Therapeutic measures were taken as a result of  all events.
got shingles after the first vac; This case was reported by a consumer via interactive digital media  and described the occurrence of shingles in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced shingles. On an unknown date, the outcome of the shingles was unknown.   It was unknown if the reporter considered the shingles to be related to Shingles vaccine.  Additional details were provided as follows: Age at vaccination was not reported. The patient received 1st dose of shingles vaccine and experienced shingles. No other information provided.
Chills, 2 hrs, followed by fever 101.8, 9 hrs, 1 ibuprofen at 200 mg at 8:00PM
approx 12days p/vax pt had episode of flaccidity, cyanosis, & staring off into space. treated @ ER as seizure initially w/dilantin. bloody stool passed & dx of intussusception;head MRI;EEG;CBC;lytes;stool cx-all neg
Adult received Pediatric dose; Adult received Pediatric dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of underdose in a 27-year-old female patient who received HBV (Engerix B 10 mcg) (batch number N73FA, expiry date 31-MAY-2024) for prophylaxis.   On 19-APR-2023, the patient received Engerix B 10 mcg 10 mcg/mg. On 19-APR-2023, an unknown time after receiving Engerix B 10 mcg, the patient experienced underdose (Verbatim: Adult received Pediatric dose) and adult use of a child product (Verbatim: Adult received Pediatric dose). The outcome of the underdose and adult use of a child product were unknown.   Additional Information: GSK Receipt Date: 21-APR-2023 The vaccine administration facility was the same as primary reporter. The reporter consented to follow up via email. The adult patient received Engerix-B 10 mcg, which led to underdose and adult use of a child product.
Patient inadvertently received a pediatric Hep A vaccine instead of a pediatric Hep B vaccine. Parents notified, and patient was given the correct Pediatric Hep B vaccine. No adverse reactions reports at this time. Patient's pediatrician, notified.
This spontaneous report as received from a healthcare worker refers to unspecified number of patients of unknown demographics. On unspecified dates the patients were vaccinated with improperly stored VARIVAX (Merck) (lot # L010144, expiry: 24-MAR-2017) (incorrect product storage). No adverse symptoms reported. The outcome was unknown. No product quality complaint was involved. This case is also related to MARRS# 1511USA014841 (same reporter link). Additional information has been requested.
Information has been received from a physician concerning a 7 year old health male child who on 19-JUN-2007 was vaccinated with Zostavax (Oka/Merck) (lot # 657558/0461U) instead of booster for Varivax (Oka/Merck) (MSD). No symptoms were reported. The physician noted that these cases of human error, not product confusion. This is one of 2 reports received from the same source. Additional information has been requested.
she said she was very sick; This spontaneous case was reported by a consumer and describes the occurrence of ILLNESS (she said she was very sick) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 01-Apr-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced ILLNESS (she said she was very sick). At the time of the report, ILLNESS (she said she was very sick) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant and Treatment medications were not provided by reporter.